Latest Quebec News
Radio-Canada | Info | A-la-une
Taïwan et plusieurs alliés de Washington retiennent leur souffle avant le sommet Trump-Xi
Au Japon, aux Philippines et en Corée du Sud, les gouvernements suivent également la rencontre avec nervosité.
Radio-Canada | Info | A-la-une
« Aller aux toilettes devient une épreuve quotidienne d’humiliation »
Témoignages de déplacés de guerre au Liban, qui n'ont pas accès à des installations sanitaires de base.
Politique - Le Devoir
La défense nationale du Canada reste liée de près aux États-Unis
La réalité tempère la rhétorique mise de l’avant par Ottawa, note la cheffe d’état-major Jennie Carignan en entrevue.
Politique - Le Devoir
Un vote de 50%+1 est encore et toujours légitime, réaffirment les élus à Québec
L’Assemblée nationale a adopté à l’unanimité une motion rappelant la validité d’une majorité absolue.
LaPresse.ca - Actualités
Transports en direct | Rien à signaler
Quelque chose à signaler sur les routes ou sur les rails ? La Presse examine le réseau en cette heure de pointe matinale et précise la couleur des feux de circulation.
LaPresse.ca - Actualités
Ce qu’on suit ce mercredi | Violence conjugale, Artemis II, Canadien
Voici les évènements au programme aujourd’hui.
Montreal Gazette
Electra Awards Solvent Extraction Construction Package
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) has awarded a C$25 million construction package to complete the solvent extraction (“SX”) building at its cobalt sulfate refinery complex north of Toronto. The contract was awarded to WB Melback Corporation, a locally based company specializing in industrial construction and maintenance. The package includes concrete and civil works, structural steel erection, piping installation, and electrical and instrumentation integration associated with the refinery’s SX circuit. Electra has issued a Limited Notice to Proceed to authorize early execution activities while the parties finalize a definitive construction agreement. Early execution activities currently underway include engineering verification, construction sequencing, quality assurance and health, safety, and environment (QA/HSE) preparation, shop drawing development, material verification, site investigations, and enabling civil and structural work to support mobilization and construction execution. “The project remains aligned with our budget and schedule expectations,” said Paolo Toscano, Vice President, Projects & Engineering. “With key construction packages awarded, long-lead equipment delivered, and contractors mobilized on site, we are moving through the construction and toward commissioning next year. Safety remains foundational to every stage of the project, and our teams and contractors continue to maintain a disciplined approach to safe execution as we continue to advance the project.” Recent work completed at the site includes: Mobilization of construction management, inspection, and contractor coordination teams across the refinery site Completion of concrete work for the pregnant leach solution filter Completion of concrete work and installation of the steel structure for the neutralization clarifier Delivery and staging of major long-lead equipment and process materials Refinery-wide quantity verification, spool development, and tie-in planning activities Demolition preparation and sequencing reviews for retrofit installation scopes Construction work underway across the refinery complex includes: SX building site preparation and enabling civil works Material staging and structural steel coordination within refinery laydown areas Neutralization clarifier installation Crystallizer piping fabrication and spool package development Process equipment installation activities across refinery systems Piping fabrication, fit-up, and tie-in activities Shop drawing execution and field material verification for SX construction scopes Skilled trades, engineering teams, construction management personnel, and specialized contractors have been mobilized to site, executing planning and construction activities. About Electra Battery Materials Electra is a leader in advancing North America’s critical minerals supply chain for lithium-ion batteries. The Company’s primary focus is constructing North America’s only cobalt sulfate refinery, as part of a phased strategy to onshore critical minerals refining and reduce reliance on foreign supply chains. In addition to the Refinery, Electra holds a significant land package in Idaho’s Cobalt Belt, including its Iron Creek project and surrounding properties, positioning the Company as a potential cornerstone for North American cobalt and copper production. Electra is also advancing black mass recycling opportunities to recover critical materials from end-of-life batteries, while continuing to evaluate growth opportunities in nickel refining and other downstream battery materials. For more information, please visit www.ElectraBMC.com. ContactHeather SmilesVice President, Investor Relations & Corporate Development Electra Battery Materialsinfo@ElectraBMC.com1.416.900.3891 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements, including statements regarding the approved construction budget and its sufficiency; project milestones such as contract awards, site mobilization, commissioning, mechanical completion, commercial production and ramp-up; targeted throughput and production volumes; additional capital required for commissioning and working capital; engineering studies and incremental investments; availability of equipment, reagents, feedstock and other inputs; commercial arrangements; and the availability and timing of governmental or other financial support. Generally, forward-looking statements can be identified by the use of terminology such as “plans”, “expects’, “estimates”, “intends”, “anticipates”, “believes” or variations of such words, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved” or similar expressions and are based on current assumptions and expectations. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, and opportunities to differ materially from those implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are set forth in the management discussion and analysis and other disclosures of risk factors for Electra Battery Materials Corporation, at www.sedarplus.com and on EDGAR at www.sec.gov. Although Electra Battery Materials Corporation believes that the information and assumptions used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, Electra Battery Materials Corporation disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A photo accompanying this announcement is available at The post Electra Awards Solvent Extraction Construction Package appeared first on Montreal Gazette.
Montreal Gazette
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
Case study presented highlighted clinical experience with revyve® in complex wound care WINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today its participation in the World Council of Enterostomal Therapists and Nurses Specialized in Wound, Ostomy and Continence Canada (“WCET–NSWOCC”) 2026 Joint Congress, held April 24–28, 2026, in Vancouver, British Columbia. The WCET–NSWOCC Joint Congress brings together global clinical leaders in wound, ostomy and continence care. Kane Biotech participated as an exhibitor and presenter, focusing on educating clinicians on the clinical benefits of revyve Antimicrobial Wound Gel, part of the revyve product family cleared by the U.S. FDA and authorized for sale in Canada. FDA cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray At the Congress, Kane Biotech presented a scientific poster: “Re‑Balancing the Wound Environment Leads to Progressive Wound Healing in High‑Risk Patients: A Case Study Using a New Thermo‑Reversible Wound Gel.” The case study demonstrated how rebalancing the wound environment supported progression toward healing in a complex diabetic foot ulcer, highlighting the potential to improve patient outcomes and quality of life. The link to the presentation can be found here. Throughout the Congress, Kane Biotech engaged directly with wound care nurses, physicians, and advanced practitioners from Canada and international markets, with a strong emphasis on clinical education. Discussions focused on challenges in chronic wounds, the impact of biofilm on delayed healing, and how antimicrobial approaches like revyve can be integrated into standard care. The Company observed strong interest from clinicians seeking evidence-based solutions to improve healing outcomes. “The WCET–NSWOCC Congress was a great opportunity to connect directly with clinicians,” said Patti Burke-Martin, Vice President of Business Development, Canada. “The discussions reinforced the importance of education in helping clinicians improve patient outcomes, while also supporting our commercialization efforts.” Participation in WCET–NSWOCC 2026 as an important part of Kane’s strategy to educate the global wound care community and advance evidence-based approaches to improving patient quality of life. About Kane Biotech Inc. (TSX-V:KNE) Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca. Join Kane’s Distribution List & Social Media:To stay informed on the latest developments, sign up for the Company’s email distribution list here. Follow Kane Website: kanebiotech.com LinkedIn: Presentation: Disrupting Biofilms to Save Limbs and Transform Wound Care For more information: Dr. Robert Huizinga Ray Dupuis Interim CEO Chief Financial Officer Kane Biotech Inc. Kane Biotech Inc. rhuizinga@kanebiotech.com rdupuis@kanebiotech.com (780) 970-1100 (204) 298-2200 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Caution Regarding Forward-Looking Information This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive. A photo accompanying this announcement is available at The post Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress appeared first on Montreal Gazette.
CBC | Canada News
Canada's new asylum law leaves 2SLGBTQ+ claimants fearing deportation
Ahmed came to Canada as an international student planning to return home — until falling in love with another man forced him to confront the dangers he says he faces in Pakistan. Now, a new federal asylum law could make his refugee claim ineligible before he even got a hearing.
CBC | Canada News
No apology included in proposed $30M settlement for Christian Brothers abuse case
Some former students of Vancouver College say a proposed $30-million settlement is meaningless without an apology and an admission of liability for the abuse they allegedly suffered at the hands of Christian Brothers linked to the Mount Cashel Orphanage.
CBC | World News
Fentanyl ingredients entering Canada via Vancouver en route to cartel-run drug labs, U.S. DEA boss says
Chemicals used to make fentanyl are streaming into the Port of Vancouver on their way to drug labs run by Mexican cartels on Canadian soil, the head of the U.S. Drug Enforcement Administration told senators in Washington, D.C., on Tuesday.
CBC | World News
Is there a Diet Coke shortage? What to know about India's 'candemic'
A scarcity of aluminum cans due the war in Iran means there's a Diet Coke shortage in India, where the drink only comes in cans. As a result, people there are hoarding the beverages and throwing parties to celebrate their favourite drink.
: Montreal
Hockey fever reaches those in Montreal shelters
Stephane Vallieres remembers going to the old Montreal Forum at age 12 to watch the Canadiens play the Quebec Nordiques like it was yesterday.
: Montreal
Call of the Wilde: Buffalo Sabres even series, edge Montreal Canadiens 3-2
After Game 4 between the Habs and the Sabres, the series is tied. It's not supposed to be easy in the playoffs, and it certainly isn't. Brian Wilde has more.
BBC News
Trump's 'Golden Dome' will cost $1.2tn and might not stop all-out missile attack
That pricetag is nearly seven times higher than Trump's initial estimate, found an independent budget office.
BBC News
Lawsuit seeks to halt Trump's $13m makeover of Lincoln Memorial Reflecting Pool
The no-bid contract went to a firm company, which critics say bypassed a rule for competing offers.
Al Jazeera – Breaking News, World News and Video from Al Jazeera
Israel bulldozes Palestinian shops to make way for settlement-linked road
Israel bulldozes Palestinian shops to make way for settlement-linked road
Al Jazeera – Breaking News, World News and Video from Al Jazeera
Gang violence displaces hundreds in Haiti’s capital
People in Cite Soleil neighbourhood of Port-au-Prince protest as gang violence shuts hospitals and displaces hundreds.